China Health Industries Holdings, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2018
February 14, 2019 at 04:13 pm
Share
China Health Industries Holdings, Inc. announced earnings results for the second quarter ended December 31, 2018. For the second quarter, the company announced sales was USD 2.714 million compared to USD 1.809 million a year ago. Operating income was USD 1.477 million compared to operating loss of USD 36,393 a year ago. Net income was USD 1.117 million compared to net loss of USD 110,573 a year ago. Basic earnings per share from continuing operations was USD 0.017 compared to basic loss per share from continuing operations of USD 0.002 a year ago. Diluted earnings per share from continuing operations was USD 0.017 compared to diluted loss per share from continuing operations of USD 0.0017 a year ago. For the half year, sales was USD 4.855 million compared to USD 3.325 million a year ago. Operating income was USD 2.389 million compared to operating loss of USD 199,765 a year ago. Net income was USD 1.749 million compared to net loss of USD 289,743 a year ago. Basic earnings per share from continuing operations was USD 0.027 compared to basic loss per share from continuing operations of USD 0.004 a year ago. Diluted earnings per share from continuing operations was USD 0.0267 compared to diluted loss per share from continuing operations of USD 0.0044 a year ago.
China Health Industries Holdings, Inc. is a manufacturer of health food products. The Company's principal business operations are conducted through its subsidiaries: Harbin Humankind Biology Technology Co., Limited (Humankind) and Heilongjiang Huimeijia Pharmaceutical Co., Ltd (HLJ Huimeijia). The Company has three operating segments: Humankind, HLJ Huimeijia and others. Humankind is engaged in the manufacturing and sale of health products. HLJ Huimeijia is engaged in the manufacturing and distribution of tincture; ointments; rubber paste, including hormones; topical solution, suppositories, liniment, including traditional Chinese medicine extractions; enemas, and oral liquids. As of June 30, 2016, the Company, through Humankind manufactured and sold 14 health supplement products. As of June 30, 2016, the Company, through HLJ Huimeijia manufactured and sold 21 products. The Company's products are sold through sales agents.